Comparative Pharmacology
Head-to-head clinical analysis: ADLYXIN versus VICTOZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLYXIN versus VICTOZA.
ADLYXIN vs VICTOZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Subcutaneous injection: 10 mcg once daily within 60 minutes before the first meal of the day; may increase to 20 mcg once daily after 2 weeks.
Subcutaneous injection: 0.6 mg once daily for 1 week, then increase to 1.2 mg once daily. May further increase to 1.8 mg once daily if needed for glycemic control.
None Documented
None Documented
Terminal elimination half-life is 2–3 hours after subcutaneous administration, supporting a twice-daily dosing regimen.
After subcutaneous administration, the terminal elimination half-life is approximately 13 hours, supporting once-daily dosing.
Renal (predominantly via glomerular filtration and proteolytic degradation; approximately 35% of the dose is excreted unchanged in urine, with the remainder as metabolites and small peptides).
Liraglutide is eliminated via degradation by general proteolysis and not by specific enzymes; the intact drug is not excreted in urine or feces. Degraded metabolites are excreted via urine and feces.
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist